Tarsus Pharmaceuticals, Inc. (TARS) - Yahoo Finance

PMVP PMV Pharmaceuticals, Inc. 1.7400. +4.82%. Find the latest Tarsus Pharmaceuticals, Inc. (TARS) stock quote, history, news and other vital information to help you with your stock …

CouponFollow Extension

82%
OFF

Tarsus Pharmaceuticals, Inc. (TARS) - Yahoo Finance

2 weeks from now

PMVP PMV Pharmaceuticals, Inc. 1.7400. +4.82%. Find the latest Tarsus Pharmaceuticals, Inc. (TARS) stock quote, history, news and other vital information to help you with your stock …

yahoo.com

22%
OFF

Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call …

2 weeks from now

16 hours ago · Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and …

yahoo.com

$50
OFF

TARS Stock Price | Tarsus Pharmaceuticals Inc. Stock Quote (U.S ...

2 weeks from now

Nov 6, 2024 · Tarsus Pharmaceuticals price target raised to $50 from $39 at Raymond James, stock rated strong buy. Jun. 29, 2021 at 7:47 a.m. ET by Tonya Garcia. Tarsus …

marketwatch.com

$100
OFF

Tarsus Pharmaceuticals, Inc. (TARS) - Stock Analysis

2 weeks from now

Nov 1, 2024 · Tarsus Announces Pricing of $100.0 Million Public Offering. IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the …

stockanalysis.com

$0.61
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue ...

2 weeks from now

2 days ago · Tarsus Pharmaceuticals, Inc. (TARS Quick Quote TARS - Free Report) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of …

zacks.com

$0.61
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss ... - Yahoo …

2 weeks from now

23 hours ago · Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 …

yahoo.com

$48
OFF

Earnings Call: Tarsus Reports Record Sales For XDEMVY In Q3 2024

2 weeks from now

1 day ago · Tarsus Pharmaceuticals, Inc. (TARS) announced robust third-quarter results for 2024, with a record $48 million in net product sales for XDEMVY, an eye care treatment for demodex …

investing.com

FAQs about Tarsus Pharmaceuticals, Inc. (TARS) - Yahoo Finance Coupon?

Is Tarsus pharmaceuticals (Tars) a good stock to buy?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript May 8, 2024 Tarsus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Tarsus’s First Quarter 2024 Financial Results Conference Call. ...

Who is Tarsus pharmaceuticals?

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. ...

What did Tarsus Pharmaceuticals Inc (Tars) do in Q2 2024?

Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ... Tarsus Pharmaceuticals Inc (TARS) reports a 65% sales increase and outlines plans for continued growth and pipeline advancements. ...

Will Tarsus pharmaceuticals (Tars) beat earnings estimates?

Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? The market expects Tarsus Pharmaceuticals, Inc. (TARS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. ...

How many times has Tarsus pharmaceuticals surpassed consensus EPS estimates?

Over the last four quarters, the company has surpassed consensus EPS estimates four times. Tarsus Pharmaceuticals , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $48.12 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 11.34%. ...

Does Tarsus pharmaceuticals have a direct-to-consumer campaign?

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) secured additional commercial coverage and two large Medicare contracts, covering more than 80% of patient lives. The company launched a direct-to-consumer campaign on streaming television, which has received positive feedback and is expected to boost sales. ...